Children suffering from congenital heart disease worldwide are being let down by a paucity of research on their conditions, a review published in the European Journal of Cardio-Thoracic Surgery reports.

When it comes to TAVR, what is good for patients is good for economics too. Or more specifically, what is good for Medicare patients with severe aortic stenosis at intermediate risk for surgery is good for reductions in U.S healthcare costs. The amount depends on where you live, with CMS reimbursing much higher on the East and West Coasts versus the center of the country with valve costs remaining the same.

Patients who received a mechanical prosthesis for surgical replacement of aortic or mitral valves derived a significant long-term survival benefit versus those who received a biologic prosthesis, according to a study in the New England Journal of Medicine.

Nearly half of all valve hospitals in the U.S. are misclassified as either low- or high-performing, according to research published in JAMA Cardiology—but that problem might have a simple fix.

DUBLIN and DENVER - November 2, 2017 - Medtronic plc (NYSE:MDT) today presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting showcasing the excellent clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) platform.

DENVER — Transcatheter aortic valve replacement (TAVR) is an “economically dominant” strategy compared to surgical aortic valve replacement (SAVR) for patients with aortic stenosis at intermediate surgical risk, according to data presented by David J. Cohen, MD, MSc, Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Medtronic plc (NYSE:MDT) today presented new clinical research to support the positive clinical performance of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe, symptomatic, aortic stenosis patients. Outcomes from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial and the Evolut R FORWARD “real-world” study were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, reinforcing the valve’s strong performance in healthier, more active patients.

Research examining 278 patients with in-stent restenosis (ISR) found that drug-eluting balloon (DEB) was non-inferior in comparison with drug-eluting stent (DES) in terms of six-month minimal lumen diameter (MLD).